Clinical trial · Observational
Multiplex Analysis of Circulating Tumor DNA
The Clinical Applications of Multiplex Analysis of Circulating Tumor DNA Biomarkers in Lung Cancer Patients
NCT03301961CI-TRIAL-00043210unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is the leading cause of cancer-related death in China. This study will explore the applications of multiplex analysis of circulating tumor DNA biomarkers for diagnosis and surveillance of lung cancer patients
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Lung Neoplasm | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The sensitivity and specificity of multiplex peripheral blood ctDNA biomarkers in the diagnosis of non-small cell lung cancer
- timeFrame
- 12 months
Secondary outcomes (3)
- measure
- Comparing the sensitivity and specificity of each peripheral blood biomarkers for the diagnosis of non-small cell lung cancer
- timeFrame
- 12 months
- measure
- The sensitivity and specificity of multiplex peripheral blood ctDNA biomarkers for tumor relapse detection
- timeFrame
- 36 months
- measure
- Lead time of tumor relapse detection by multiplex ctDNA biomarkers than radiographic approaches
- timeFrame
- 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Sign informed consent and consent to participate in this study; 2. Found small nodules in pulmonary by CT and prepare for surgery; Exclusion Criteria: 1. Malignant tumor history within the past 5 years; 2. Receiving chemotherapy, radiotherapy or targeted therapy before surgery; 3. No matching tissue or blood samplesUnqualified blood samples 4. Lesion is pure ground glass opacity.
References
Publications (0)
Data not yet available
No reference posted for this study.